News

Genentech‘s Rituxan (rituximab) is safe and effective to induce and maintain remission in patients with refractory or relapsing granulomatous manifestations (inflamed tissue) due to granulomatosis with polyangiitis (GPA), according to a new study. The findings were presented at the recent 19th International Vasculitis and ANCA Workshop in Philadelphia, Pennsylvania,…

While breathing difficulties in ANCA-associated vasculitis patients are often a symptom of worsening vasculitis in their lungs, doctors should also consider cardiac valve involvement — or damage to heart valves — as a possible cause, a case report suggests. The study, “Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Causes Aortic…

Intravenous immunoglobulin therapy – which essentially consists on pooled antibodies from a thousand or more blood donors – could be a promising way of treating MPO-positive ANCA-associated vasculitis patients, an early study suggests. In a rat model of the disease, this therapy lowered the number of anti-MPO antibodies, reduced neutrophil traps –…

Some patients with microscopic polyangiitis (MPA) produce antibodies against antimicrobial traps that may partly explain why these traps are capable of withstanding normal degradation, a study says. The study, “The presence of anti-neutrophil extracellular trap antibody in patients with microscopic polyangiitis,” was published in the journal Rheumatology.

A molecule known as chemokine receptor 8 (CCR8) can be seen at significantly high levels in people with active ANCA-associated vasculitis and serve as a blood biomarker of disease activity of importance to treatment, because its serum levels do not alter with infections, a study in Japan reports. Specifically, blood serum…

Eosinophils, a type of immune cell, appear to contribute to the inflammatory process seen in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), a study shows. The study, “Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis,” was published in the journal BMC Rheumatology. ANCA-associated…

A large proportion of patients with ANCA-associated vasculitis (AAV) who develop orbital mass, an eye complication, respond poorly to treatment, a study reports. Future studies need to evaluate the use and effectiveness of combination therapies for the subgroup of patients that are more likely to develop this condition, according…

Patients with ANCA-associated vasculitis producing PR3-ANCA antibodies may have inadequate blood delivery to internal organs, such as the kidneys and spleen, leading to organ malfunction and pain, a case report suggests. The study, “PR3 vasculitis presenting with symptomatic splenic and renal infarction: a case report and…

Testing positive for anti-PR3 antibodies and showing lesions in the lungs and cartilaginous tissues could replace nasal biopsy for diagnosing patients with suspected granulomatosis with polyangiitis (GPA) and chronic rhinosinusitis, according to a pilot study. The study, “Should nasal biopsy inevitably be performed for…

Patients with ANCA-associated vasculitis (AAV) who have persistent antiphospholipid antibodies (APLAs) at diagnosis are at a greater risk of developing blood clots, with consequent obstruction of the blood flow, according to new research. The study, “Persistent antiphospholipid antibodies are associated with thrombotic events in ANCA-associated vasculitis: A retrospective…